Evidence map›Paper›PMID 33753213›Full record

ArticleEuropean journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V2021

Microparticle encapsulation of a tuberculosis subunit vaccine candidate containing a nanoemulsion adjuvant via spray drying.

Mellissa Gomez, Michelle Archer, David Barona, Hui Wang, Mani Ordoubadi, Shabab Bin Karim, Nicholas B Carrigy, Zheng Wang, Joseph McCollum, Chris Press and 4 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Article
  9. Article
  10. Development of thermostable vaccine adjuvants.Expert review of vaccines · 2021
    Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 2 countries.

Mellissa GomezDepartment of Mechanical Engineering, University of Alberta, Edmonton, AB, Canada.
Michelle ArcherInfectious Disease Research Institute, Seattle, WA, USA.
David BaronaDepartment of Mechanical Engineering, University of Alberta, Edmonton, AB, Canada.
Hui WangDepartment of Mechanical Engineering, University of Alberta, Edmonton, AB, Canada.
Mani OrdoubadiDepartment of Mechanical Engineering, University of Alberta, Edmonton, AB, Canada.
Shabab Bin KarimDepartment of Mechanical Engineering, University of Alberta, Edmonton, AB, Canada.
Nicholas B CarrigyDepartment of Mechanical Engineering, University of Alberta, Edmonton, AB, Canada.
Zheng WangDepartment of Mechanical Engineering, University of Alberta, Edmonton, AB, Canada.
Joseph McCollumInfectious Disease Research Institute, Seattle, WA, USA.
Chris PressInfectious Disease Research Institute, Seattle, WA, USA.
Alana GerhardtInfectious Disease Research Institute, Seattle, WA, USA.
Christopher B FoxInfectious Disease Research Institute, Seattle, WA, USA; Department of Global Health, University of Washington, Seattle, WA, USA.
Ryan M KramerInfectious Disease Research Institute, Seattle, WA, USA.
Reinhard VehringDepartment of Mechanical Engineering, University of Alberta, Edmonton, AB, Canada. Electronic address: reinhard.vehring@ualberta.ca.
University of Alberta · CAInfectious Disease Research Institute · US

Funding

NIAID NIH HHS HHSN272201400041C
6 · The paper itself

Abstract

Spray drying is a technique that can be used to stabilize biopharmaceuticals, such as vaccines, within dry particles. Compared to liquid pharmaceutical products, dry powder has the potential to reduce costs associated with refrigerated storage and transportation. In this study, spray drying was investigated for processing an adjuvanted tuberculosis subunit vaccine, formulated as an oil-in-water nanoemulsion, into a dry powder composed of microparticles. Applying in-silico approaches to the development of formulation and processing conditions, successful encapsulation of the adjuvanted vaccine within amorphous microparticles was achieved in only one iteration, with high retention (>90%) of both the antigen and adjuvant system. Moisture-controlled stability studies on the powder were conducted over 26 months at temperatures up to 40 °C. Results showed that the powder was physically stable after 26 months of storage for all tested temperatures. Adjuvant system integrity was maintained at temperatures up to 25 °C after 26 months and after one month of storage at 40 °C. The spray-dried product demonstrated improved antigen thermostability when stored above refrigerated temperatures as compared to the liquid product. These results demonstrate the feasibility of spray drying as a method of encapsulating and stabilizing an adjuvanted vaccine.

Indexed as

Spray DryingAdjuvants, ImmunologicChemistry, PharmaceuticalDrug CompoundingDrug StabilityDrug StorageEmulsionsExcipientsHumansNanoparticlesParticle SizePowdersTuberculosisTuberculosis VaccinesVaccines, SubunitAdjuvants, ImmunologicEmulsionsExcipientsPowdersTuberculosis VaccinesVaccines, SubunitAdjuvant emulsionGel microparticlesNano-encapsulationPhysical stabilityVaccine spray drying

Identifiers

PMID33753213
PMCPMC8096719
OpenAlexW3138267048

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.